VivoSeq
Nephrology

Impaired Renal Function

0

Pipeline Programs↗

2

Active Trials↗

32

Companies Involved↗

Impaired Renal Function is an early-stage landscape with 0 programs across 32 companies. The most active players are Merck & Co., Gilead, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalGilead logo

Gilead

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

PreclinicalNovo Nordisk logo

Novo Nordisk

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

75

clinical trials

Completed60 · 80%
Terminated7 · 9%
Unknown status5 · 7%
Withdrawn1 · 1%
Recruiting1 · 1%
Active, not recruiting1 · 1%

Clinical Trials

Trial Activity

75 trials

Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
Recruiting·SSparrow Pharmaceuticals·Phase 1·NCT07227922·16 enrolled
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
Active, not recruiting·SShanton Pharma Pte. Ltd.·Phase 1/2·NCT06729853·32 enrolled
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
Completed·Novo Nordisk logoNovo Nordisk·Phase 1·NCT03186495·44 enrolled
A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function
Completed·NNicOx·Phase 1·NCT00674856·32 enrolled
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
Completed·Amgen logoAmgen·Phase 1·NCT01331941·35 enrolled
Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function
Completed·PPhaseBio Pharmaceuticals Inc.·Phase 1·NCT01478399·16 enrolled
Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function
Completed·LLebanese American University·Phase 4·NCT03158792·32 enrolled
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
Completed·AAmicus Therapeutics·Phase 1·NCT01730469·32 enrolled
Study of Aldafermin (NGM282) in Participants With Impaired Renal Function
Completed·NNGM Biopharmaceuticals, Inc·Phase 1·NCT04179630·48 enrolled
Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function
Completed·SShanghai Shengdi Pharmaceutical Co., Ltd·Phase 1·NCT06657560·41 enrolled
A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function
Completed·CCougar Biotechnology, Inc.·Phase 1·NCT01715259·16 enrolled
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function
Completed·Eisai logoEisai·Phase 1·NCT01418677·19 enrolled
Study of AT-527 in Subjects With Normal and Impaired Renal Function
Completed·AAtea Pharmaceuticals, Inc.·Phase 1·NCT05618314·36 enrolled
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function
Completed·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 1·NCT06929156·34 enrolled
Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function
Completed·Takeda logoTakeda·Phase 1·NCT01716455·66 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)